Monovalent inactivated influenza vaccine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pre-pandemic Influenza Vaccine
Conditions
Pre-pandemic Influenza Vaccine
Trial Timeline
Nov 1, 2008 → Jun 1, 2009
NCT ID
NCT00848029About Monovalent inactivated influenza vaccine
Monovalent inactivated influenza vaccine is a phase 3 stage product being developed by Novartis for Pre-pandemic Influenza Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT00848029. Target conditions include Pre-pandemic Influenza Vaccine.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00841646 | Phase 2 | Completed |
| NCT00848029 | Phase 3 | Completed |